FDA concludes Treanda will benefit from Bendeka's exclusivity protection

FDA concluded that the scope of Orphan Drug exclusivity for cancer drug Bendeka bendamustine from Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) extends to all applications containing the same active ingredient unless a sponsor shows clinical superiority to Bendeka. The

Read the full 377 word article

How to gain access

Continue reading with a
two-week free trial.